Corxel Pharmaceuticals
As of the edition of 20 October 2026, Corxel Pharmaceuticals runs 5 drugs, 3 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 2 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Aficamten | Ends 2039 (patent) | 1 |
| Etripamil | Ends 2030 (exclusivity) | 1 |
| Aceclidine | Ends 2030 (exclusivity) | 0 |
A route B row is one company at one target.
Where its trials are
- Heart and blood vessels: 5 trials led
- Nutrition and metabolism: 3 trials led
- Eye: 2 trials led